Filtering options
Pharma
MedTech
EU
US
M&A
CDD/VDD
Asia-Pac
Biotech
CDMO
Medical Devices
Digital Therapeutics
2025
EU
CDD/VDD
CDD Advisor: Fremman Capital Acquires DIESSE Diagnostica Senese from Archimed
Alira Health advised Fremman Capital, a pan-European, mid-market investment firm with offices in London, Luxembourg, Madrid, Munich, and Paris, in a Commercial Due Diligence of DIESSE Diagnostica Senese, a leading producer of innovative diagnostic systems and dedicated reagents for the specialty In-Vitro Diagnostics market. DIESSE Diagnostica Senese focuses mainly on diagnostics for autoimmune and infectious diseases, and hematology measurement systems. The company offers one of the broadest portfolios of specialty immunoassay tests in the market, with more than 170 tests available on its fully automated instruments.
2025
EU
CDD/VDD
CDD Advisor: Impact Expansion Invests in neurocare Group AG
Alira Health advised Impact Expansion on an investment into neurocare group AG. The Munich-based leader in personalized mental health care has partnered with Impact Expansion, a private equity firm focused on supporting companies with a strong social and environmental impact.
2024
Pharma
EU
Biotech
Exclusive Transaction Advisor: LINDIS Biotech License-out Korjuny (Catumaxomab) to Pharmanovia
Alira Health supported LINDIS Biotech in entering a license agreement with Pharmanovia for Europe for KORJUNY® (catumaxomab), indicated for the treatment of malignant ascites.
Catumaxomab was originally granted marketing authorization under the brand name Removab in the EU on April 20, 2009, for the treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is unavailable or no longer feasible. Catumaxomab was the first T-cell engager trifunctional antibody and the first drug in the world approved specifically for the treatment of malignant ascites. It has demonstrated safety and anti-tumor efficacy in more than 2,000 patients. The product has not been marketed since 2014 and was withdrawn from the EU on June 2, 2017, for commercial reasons.
On October 17, 2024, LINDIS Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the brand name KORJUNY®. Approval is expected by the end of 2024, making it the only drug treatment for malignant ascites.
Catumaxomab was originally granted marketing authorization under the brand name Removab in the EU on April 20, 2009, for the treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is unavailable or no longer feasible. Catumaxomab was the first T-cell engager trifunctional antibody and the first drug in the world approved specifically for the treatment of malignant ascites. It has demonstrated safety and anti-tumor efficacy in more than 2,000 patients. The product has not been marketed since 2014 and was withdrawn from the EU on June 2, 2017, for commercial reasons.
On October 17, 2024, LINDIS Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the brand name KORJUNY®. Approval is expected by the end of 2024, making it the only drug treatment for malignant ascites.
2024
EU
M&A
Asia-Pac
M&A Sell-Side Advisor: Se Soigner Acquires MedicOeil from Hoya Corporation
Alira Health advised Hoya Corporation, a Japanese conglomerate specializing in ophthalmology, in the sale of its subsidiary, MedicOeil, to Se Soigner, a French healthcare provider. This transaction involved the divestiture of MedicOeil, a non-core business unit of Hoya, focused on managing ophthalmology clinics. The sale to Se Soigner not only secures continued employment for the staff but also supports MedicOeil's mission to enhance medical care accessibility in remote areas.
2024
MedTech
CDMO
M&A Sell-Side Advisor: Gilero LLC Acquired by Sanner
Alira Health advised Gilero, a medical device design and manufacturing organization, in its acquisition by Sanner Group, a global leader in healthcare packaging solutions and a portfolio company of GHO Capital. This strategic enhances Sanner’s product development capabilities and expands its presence in the U.S. market. The partnership is set to drive innovation and add value across the medical technology and drug delivery sectors. We were privileged to support Gilero in this process, ensuring a successful outcome.
2024
Pharma
Strategic and Financial Advisor: Klinge Biopharma GmbH enters into an exclusive licensing and supply agreement with MS Pharma
Alira Health has acted as the exclusive financial and strategic advisors to Klinge Biopharma GmbH, licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea® (Aflibercept), in the Middle East and North Africa.
2024
CDD/VDD
Digital Therapeutics
CDD Advisor: TVM Capital Healthcare Invests in neurocare Group AG
Alira Health advised TVM Capital Healthcare on an investment into neurocare group AG. The Munich-based leader in personalized mental health care is set to receive a US$ 17 million boost from TVM Capital Healthcare, a specialist healthcare private equity firm.
2024
MedTech
CDD/VDD
CDMO
CDD Advisor: Trill Impact Enters a Strategic Alliance with TT medic
Alira Health advised Trill Impact, a pioneering Impact House with around EUR 1.2 billion in assets under management, joining forces with TT medic GmbH, a medtech development and manufacturing partner for high-quality polymer components operating in Austria, Switzerland and Germany.